Actually, ABT is conducting seven all-oral phase-3 HCV trials for genotype-1 patients: the three I cited in #msg-81374289 and four others called SAPHIRE-III, SAPHIRE-IV, TURQUOISE-I, AND PEARL-II.
SAPHIRE-III and SAPHIRE-IV (unlike SAPHIRE-I and –II, where all patients receive ribavirin and the control arm is 12 weeks of full-fledged placebo) test 12 weeks of ABT’s 3-DAA combination +/- ribavirin. SAPHIRE-III is for treatment-naïve genotype-1b and SAPHIRE-IV is for treatment-naïve genotype-1a.
PEARL-II is a clone of SAPHIRE-III except that it is for treatment-experienced genotype-1b patients.
TURQUOISE-I tests HCV/HIV co-infected patients using 12- and 24-week arms of ABT’s 3-DAA cocktail + ribavirin.
All told, these phase-3 trials will have about 2,000 patients. (Source: Today’s AASLD CC.)
News 
Market Data 
Discover 
